{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:51:23Z","timestamp":1790743883065,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.08.026","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T05:47:07Z","timestamp":1629265627000},"page":"7308-7318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1859-6688","authenticated-orcid":false,"given":"Donald L.","family":"Lamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0815-7080","authenticated-orcid":false,"given":"Alvaro","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.08.026_b0005","first-page":"1","volume":"276","author":"Nauts","year":"1953","journal-title":"Acta Med Scand Suppl"},{"key":"10.1016\/j.vaccine.2021.08.026_b0010","unstructured":"Pearl R: Cancer and tuberculosis. Am J Hyg. 1929 9:97, (as quoted by Ad P.M vander Meijden, Frans M.J Debruyne, Peter A Steerenberg, Wim H. de Jong: Aspects of Non-specific Immunotherapy with BCG in Superficial Bladder cancer: An Overview. Progress in Clinical and Biological Research, 310: EORTC Genitourinary Group Monograph 6. BCG in superficial bladder cancer. 1989;11-33, C Alan R. Liss, Inc.)"},{"key":"10.1016\/j.vaccine.2021.08.026_b0015","doi-asserted-by":"crossref","unstructured":"Lewis PA, Loomis D. ALLERGIC IRRITABILITY : IV. THE CAPACITY OF GUINEA PIGS TO PRODUCE ANTIBODIES AS AFFECTED BY THE INHERITANCE AND AS RELATED TO FAMILIAL RESISTANCE TO TUBERCULOSIS. J Exp Med. 1928 Feb 29;47(3):437-48. doi: 10.1084\/jem.47.3.437. PMID: 19869422; PMCID: PMC2131388.","DOI":"10.1084\/jem.47.3.437"},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.026_b0020","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"BCG immunotherapy of malignant melanoma: summary of a seven-year experience","volume":"180","author":"Morton","year":"1974","journal-title":"Ann Surg"},{"key":"10.1016\/j.vaccine.2021.08.026_b0025","doi-asserted-by":"crossref","unstructured":"Davignon L, Lemonde P, St-Pierre J, Frappier A. B.C.G. vaccination and leukaemia mortality. Lancet. 1971 Jan 9;1(7689):80-1. doi: 10.1016\/s0140-6736(71)90804-x. PMID: 4099240.","DOI":"10.1016\/S0140-6736(71)90804-X"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.026_b0030","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jama.1972.03210120041010","article-title":"BCG vaccination and leukemia mortality","volume":"222","author":"Rosenthal","year":"1972","journal-title":"JAMA"},{"issue":"7597","key":"10.1016\/j.vaccine.2021.08.026_b0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(69)92648-8","article-title":"Active immunotherapy for acute lymphoblastic leukaemia","volume":"1","author":"Math\u00e9","year":"1969","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.026_b0040","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archinte.1985.00360060062007","article-title":"High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine","volume":"145","author":"Hewlett","year":"1985","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.vaccine.2021.08.026_b0045","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1985.3.10.1318","article-title":"Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study","volume":"3","author":"Jones","year":"1985","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.026_b0050","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJM198403223101201","article-title":"Adjuvant therapy of colon cancer\u2013results of a prospectively randomized trial","volume":"310","author":"Gastrointestinal Tumor Study Group","year":"1984","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2021.08.026_b0055","doi-asserted-by":"crossref","unstructured":"Creasman 1 WT, Omura GA, Brady MF, Yordan E, DiSaia PJ, J Beecham: A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;39(3):239-43. PMID: 2258063 doi: 10.1016\/0090-8258(90)90244-f.","DOI":"10.1016\/0090-8258(90)90244-F"},{"key":"10.1016\/j.vaccine.2021.08.026_b0060","doi-asserted-by":"crossref","unstructured":"Toomes H. Postoperative immunostimulation in non-small-cell bronchial carcinoma. Outcome and complications.Dtsch Med Wochenschr 1984; 109(24):935-40. PMID: 6376041.","DOI":"10.1055\/s-2008-1069300"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.026_b0065","first-page":"744","article-title":"T a McPherson: adjuvant BCG immunotherapy for malignant melanoma","volume":"131","author":"Paterson","year":"1984","journal-title":"Can Med Assoc J"},{"issue":"25","key":"10.1016\/j.vaccine.2021.08.026_b0070","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJM197406202902506","article-title":"BCG and cancer (first of two parts)","volume":"290","author":"Bast","year":"1974","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.vaccine.2021.08.026_b0075","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1056\/NEJM197406272902605","article-title":"BCG and cancer","volume":"290","author":"Bast","year":"1974","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.026_b0080","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0022-5347(17)53354-6","article-title":"Immunotherapy of murine transitional cell carcinoma","volume":"128","author":"Lamm","year":"1982","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.026_b0085","first-page":"2672","article-title":"Antibody responses to Bacillus Calmette-Gu\u00e9rin during immunotherapy in bladder cancer patients","volume":"41","author":"Winters","year":"1981","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.026_b0090","first-page":"369","article-title":"Bacillus Calmette-Gu\u00e9rin and dinitrochlorobenzene immunotherapy of chemically induced bladder tumors","volume":"14","author":"Lamm","year":"1977","journal-title":"Invest Urol"},{"key":"10.1016\/j.vaccine.2021.08.026_b0095","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4:137ra72","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2021.08.026_b0100","doi-asserted-by":"crossref","unstructured":"Svatek RS, Tangen C, Delacroix S, Lowrance W, Lerner SP. Background and Update for S1602 \u201cA Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-na\u00efve High-grade Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2018 Jul; 4(4):522-524. Doi: 10.1016\/j.euf.2018.08.015. Epub 2018 Sep 6. PMID: 30197040; PMCID: PMC6581029.","DOI":"10.1016\/j.euf.2018.08.015"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.026_b0105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.026_b0110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol."},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.026_b0115","first-page":"47","article-title":"Intravesical administration of bacillus Calmette-Gu\u00e9rin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial","volume":"69","author":"Pinsky","year":"1985","journal-title":"Can Treat Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.026_b0120","first-page":"551","article-title":"Recurrent bladder papillomata treated with bacillus Calmette-Gu\u00e9rin: a preliminary report (phase I trial)","volume":"62","author":"Douville","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.vaccine.2021.08.026_b0125","doi-asserted-by":"crossref","unstructured":"Martinez-Pi\u00f1eiro JA, Munta\u00f1ola P. Nonspecific immunotherapy with BCG vaccine in bladder tumors: a preliminary report. Eur Urol 1977;3(1):11\u201322. doi: 10.1159\/000472047. PMID: 837949 DOI: 10.1159\/000472047.","DOI":"10.1159\/000472047"},{"issue":"10","key":"10.1016\/j.vaccine.2021.08.026_b0130","first-page":"358","article-title":"Immunotherapy with oral BCG in cancer of the bladder","volume":"24","author":"Netto J\u00fanior","year":"1978","journal-title":"AMB Rev Assoc Med Bras"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.026_b0135","first-page":"417","article-title":"The BCG as coadjuvant in the treatment of bladder carcinoma] [Article in Spanish","volume":"32","author":"Rodrigues Netto Jr","year":"1979","journal-title":"Clinical Trial Arch ESP Urol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.026_b0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-5347(17)39367-9","article-title":"A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer","volume":"144","author":"Lamm","year":"1990","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.026_b0145","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0022-5347(17)38379-9","article-title":"Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma","volume":"145","author":"D'Ancona","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2021.08.026_b0150","first-page":"69","article-title":"Treatment of Carcinoma in situ of the bladder with BCG: a phase II trial Cancer Immunol Immunother 1980;9:69\u201372. Morales, A. Treatment of carcinoma in situ of the bladder with BCG","volume":"9","author":"Morales","year":"1980","journal-title":"Can Immunol Immunother"},{"issue":"17","key":"10.1016\/j.vaccine.2021.08.026_b0155","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Gu\u00e9rin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.026_b0160","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","article-title":"A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Gu\u00e9rin therapy of superficial bladder cancer","volume":"5","author":"Badalament","year":"1987","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.026_b0165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0022-5347(17)43125-9","article-title":"Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial","volume":"138","author":"Hudson","year":"1987","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.026_b0170","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","article-title":"Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and\/or high grade bladder tumors","volume":"165","author":"Palou","year":"2001","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.026_b0175","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol."},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.026_b0180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","article-title":"Maintenance therapy with bacillus Calmette-Gu\u00e9rin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer","volume":"108","author":"Hinotsu","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.vaccine.2021.08.026_b0185","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijsu.2018.02.045","article-title":"Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized clinical trials","volume":"52","author":"Chen","year":"2018","journal-title":"Int J Surg."},{"key":"10.1016\/j.vaccine.2021.08.026_b0190","doi-asserted-by":"crossref","unstructured":"B\u00f6hle A, Bock PR. Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004 Apr;63(4):682-6; discussion 686-7. doi: 10.1016\/j.urology.2003.11.049. PMID: 15072879.","DOI":"10.1016\/j.urology.2003.11.049"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.026_b0195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol."},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.026_b0200","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol."},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.026_b0205","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol."},{"key":"10.1016\/j.vaccine.2021.08.026_b0210","doi-asserted-by":"crossref","unstructured":"Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB. Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2018 Jul;4(4):512-521. doi: 10.1016\/j.euf.2018.08.019. Epub 2018 Sep 3. PMID: 30190111; PMCID: PMC7810510.","DOI":"10.1016\/j.euf.2018.08.019"},{"key":"10.1016\/j.vaccine.2021.08.026_b0215","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM; EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Gu\u00e9rin, and bacillus Calmette-Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010 May;57(5):766-73. doi: 10.1016\/j.eururo.2009.12.024. Epub 2009 Dec 18. PMID: 20034729; PMCID: PMC2889174.","DOI":"10.1016\/j.eururo.2009.12.024"},{"key":"10.1016\/j.vaccine.2021.08.026_b0220","doi-asserted-by":"crossref","unstructured":"Spencer BA, McBride RB, Hershman DL, Buono D, Herr HW, Benson MC, Gupta-Mohile S, Neugut AI. Adjuvant intravesical bacillus calmette-gu\u00e9rin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract. 2013 Mar;9(2):92-8. doi: 10.1200\/JOP.2011.000480. Epub 2012 Oct 30. PMID: 23814517; PMCID: PMC3595445.","DOI":"10.1200\/JOP.2011.000480"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.026_b0225","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/21681805.2014.968868","article-title":"Use of bacillus Calmette-Gu\u00e9rin in stage T1 bladder cancer: long-term observation of a population-based cohort","volume":"49","author":"Patschan","year":"2015","journal-title":"Scand J Urol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.026_b0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of bacillus Calmette-Gu\u00e9rin connaught strain for bladder cancer patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.026_b0235","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12916-016-0685-4","article-title":"The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality","volume":"14","author":"Harris","year":"2016","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.026_b0240","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/infdis\/jir240","article-title":"Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?","volume":"204","author":"Aaby","year":"2011","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.026_b0245","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.cmi.2019.04.020","article-title":"Non-specific effects of BCG vaccine on viral infections","volume":"25","author":"Moorlag","year":"2019","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.vaccine.2021.08.026_b0250","doi-asserted-by":"crossref","unstructured":"Lobo N, Brooks NA, Zlotta AR, Cirillo JD, Boorjian S, Black PC, Meeks JJ, Bivalacqua TJ, Gontero P, Steinberg GD, McConkey D, Babjuk M, Alfred Witjes J, Kamat AM. 100 years of Bacillus Calmette-Gu\u00e9rin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021 Jun 15:1\u201312. doi: 10.1038\/s41585-021-00481-1. Epub ahead of print. PMID: 34131332; PMCID: PMC8204595.","DOI":"10.1038\/s41585-021-00481-1"},{"key":"10.1016\/j.vaccine.2021.08.026_b0255","doi-asserted-by":"crossref","unstructured":"Triccas JA. Recombinant BCG as a vaccine vehicle to protect against tuberculosis. Bioeng Bugs. 2010 Mar-Apr;1(2):110-5. doi: 10.4161\/bbug.1.2.10483. Epub 2009 Nov 2. PMID: 21326936; PMCID: PMC3026451.Zhang W, Zhang Y, Zheng H, Pan Y, Liu H, Du P, Wan L, Liu J, Zhu B, Zhao G, Chen C, Wan K. Genome sequencing and analysis of BCG vaccine strains. PLoS One. 2013 Aug 19;8(8):e71243. doi: 10.1371\/journal.pone.0071243. PMID: 23977002; PMCID: PMC3747166.","DOI":"10.1371\/journal.pone.0071243"},{"key":"10.1016\/j.vaccine.2021.08.026_b0260","doi-asserted-by":"crossref","unstructured":"da Costa AC, Nogueira SV, Kipnis A, Junqueira-Kipnis AP. Recombinant BCG: Innovations on an Old Vaccine. Scope of BCG Strains and Strategies to Improve Long-Lasting Memory. Front Immunol. 2014 Apr 7;5:152. doi: 10.3389\/fimmu.2014.00152. PMID: 24778634; PMCID: PMC3984997.","DOI":"10.3389\/fimmu.2014.00152"},{"issue":"9","key":"10.1016\/j.vaccine.2021.08.026_b0265","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fimmu.2018.00121","article-title":"Next-generation vaccines based on Bacille Calmette-Gu\u00e9rin","volume":"5","author":"Nieuwenhuizen","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.026_b0270","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.celrep.2018.04.003","article-title":"STING-activating adjuvants elicit a Th17 immune response and protect against mycobacterium tuberculosis infection","volume":"23","author":"Van Dis","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.vaccine.2021.08.026_b0275","doi-asserted-by":"crossref","unstructured":"Alok Kumar Singh, Monali Praharaj, Kara A Lombardo, Takahiro Yoshida, Andres Matoso, Alex S. Baras, Liang Zhao, Pankaj Prasad, Jonathan D. Powell, Max Kates, David McConkey, Drew M. Pardoll, R. Bishai, Trinity J. Bivalacqua: Recombinant BCG overexpressing a STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer doi: https:\/\/doi.org\/10.1101\/2020.04.25.061531.","DOI":"10.1101\/2020.04.25.061531"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.026_b0280","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2008.11.019","article-title":"Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed","volume":"181","author":"Morales","year":"2009","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.026_b0285","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Gu\u00e9rin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.026_b0290","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer."},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.026_b0295","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2021.08.026_b0300","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000052391","article-title":"Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies","volume":"37","author":"Lamm","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.vaccine.2021.08.026_b0305","doi-asserted-by":"crossref","unstructured":"Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF. Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer. J Urol. 2013 Sep;190(3):850-6. doi: 10.1016\/j.juro.2013.03.030. Epub 2013 Mar 15. PMID: 23507396; PMCID: PMC3951790.","DOI":"10.1016\/j.juro.2013.03.030"},{"issue":"10","key":"10.1016\/j.vaccine.2021.08.026_b0310","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.026_b0315","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.026_b0320","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00345-020-03474-8","article-title":"Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions","volume":"39","author":"Pfail","year":"2021","journal-title":"World J Urol"},{"issue":"22","key":"10.1016\/j.vaccine.2021.08.026_b0325","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med."},{"issue":"6529","key":"10.1016\/j.vaccine.2021.08.026_b0330","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2101046X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2101046X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:05:49Z","timestamp":1759403149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2101046X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":66,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X2101046X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.026","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}